Estrace

"The U.S. Food and Drug Administration today approved Osphena (ospemifene) to treat women experiencing moderate to severe dyspareunia (pain during sexual intercourse), a symptom of vulvar and vaginal atrophy due to menopause.

Close clinical surveillance of all women taking estrogens is important. Adequate
diagnostic measures, including endometrial sampling when indicated, should
be undertaken to rule out malignancy in all cases of undiagnosed persistent
or recurring abnormal vaginal bleeding. There is no evidence that the use
of “natural” estrogens results in a different endometrial risk
profile than “synthetic” estrogens at equivalent estrogen doses.
(See WARNINGS, Malignant neoplasms, Endometrial cancer.)

The Women's Health Initiative Memory Study (WHIMS), a substudy of WHI, reported
increased risk of developing probable dementia in postmenopausal women 65
years of age or older during 4 years of treatment with oral conjugated estrogens
plus medroxyprogesterone acetate relative to placebo. It is unknown whether
this finding applies to younger postmenopausal women or to women taking estrogen
alone therapy. (See CLINICAL PHARMACOLOGY, Clinical
Studies.)

Other doses of oral conjugated estrogens with medroxyprogesterone acetate,
and other combinations and dosage forms of estrogens and progestins were not
studied in the WHI clinical trials and, in the absence of comparable data, these
risks should be assumed to be similar. Because of these risks, estrogens with
or without progestins should be prescribed at the lowest effective doses and
for the shortest duration consistent with treatment goals and risks for the
individual woman.

What are the precautions when taking estradiol (Estrace)?

Before taking this medication, tell your doctor or pharmacist if you are allergic to it; or if you have any other allergies. This product may contain inactive ingredients, which can cause allergic reactions or other problems. Talk to your pharmacist for more details.